0460 (0460) Fair Value & Analysis

Healthcare · Market cap HK$7.5B

0 0460 0460 · HK

PriceHK$0.8300

Fair ValueHK$0.5100

Upside-38.6%

Quality47/100

Evidence: Medium Range HK$0.3700 – HK$0.6000

Fair value as of: Jul 1, 2026

From 17 valuation models · updated today

Share price −12.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.8198 – HK$1.89 · fair‑value band HK$0.3700 – HK$0.6000 · the HK$0.8300 price screens above the HK$0.5100 fair value. As of Jul 1, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0460 (0460) currently trades at HK$0.8300, while our model-based Fair Value estimate is HK$0.5100 — implying the stock looks roughly 38.6% overvalued today. We read business quality at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 0460 generated revenue of HK$2.6B at a net margin of 6.9%. Revenue grew 54.7% year over year. It earns a return on equity of 3.1%. The balance sheet holds a net cash position of HK$2.6B. Fundamentals as of Jul 1, 2026

Key figures & financial health

Revenue (TTM) HK$2.6B

Revenue growth (YoY) +54.7%

Net margin 6.9%

Return on equity 3.1%

Free cash flow −HK$218M FY2025

P/E ratio 41.5

More key figures

Operating margin 18.4%

EPS (TTM) HK$0.0100

Dividend yield 2.3%

EPS growth (YoY) -93.3%

Net cash HK$2.6B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 1, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0460 reported revenue of HK$2.6B in FY2025 versus HK$3.0B in FY2021, a compound −3.7%/yr. Reported net income was HK$180M in FY2025, compounding −19.0%/yr from FY2021.

Revenue −3.7%/yr

FY21 HK$3.0B

FY22 HK$2.2B

FY23 HK$1.9B

FY24 HK$1.9B

FY25 HK$2.6B

Net income −19.0%/yr

FY21 HK$417M

FY22 −HK$1.9B

FY23 −HK$54.0M

FY24 −HK$217M

FY25 HK$180M

Is 0460 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 1, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥49.36	¥26.59	-46%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0460 (0460) undervalued?

As of Jul 1, 2026, our model estimates a fair value of HK$0.5100 versus a price of HK$0.8300 — about −39% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0460?

Our model-based fair value for 0460 is HK$0.5100 (as of Jul 1, 2026), built from audited fundamentals. The current price is HK$0.8300.

What is the quality score of 0460?

0460 has a Quality Score of 47/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0460 (0460)?

0460 reported trailing-twelve-month revenue of about HK$2.6B (latest available figure, as of Jul 1, 2026).

What is the net profit margin of 0460?

The net profit margin of 0460 is about 6.9%, meaning it keeps roughly 6.9% of revenue as net income. Based on the latest reported figures.

Does 0460 pay a dividend?

0460 currently shows a dividend yield of about 2.28% relative to its recent price (as of Jul 1, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.